Phase 1b study of marizomib (MRZ) in combination with temozolomide (Temodar) and radiation in newly diagnosed, Grade 4 malignant glioma

Trial Profile

Phase 1b study of marizomib (MRZ) in combination with temozolomide (Temodar) and radiation in newly diagnosed, Grade 4 malignant glioma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs Marizomib (Primary) ; Temozolomide
  • Indications Glioma
  • Focus Adverse reactions
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 21 Sep 2017 Number of arms changed from 3 to 4,hence planned patient number also changed from 48 to 60.
    • 21 Sep 2017 Planned number of patients changed from 48 to 60.
    • 24 Aug 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top